ZA201200843B - Sogma ligands for the prevention or treatment of pain induced by chemotherapy - Google Patents

Sogma ligands for the prevention or treatment of pain induced by chemotherapy

Info

Publication number
ZA201200843B
ZA201200843B ZA2012/00843A ZA201200843A ZA201200843B ZA 201200843 B ZA201200843 B ZA 201200843B ZA 2012/00843 A ZA2012/00843 A ZA 2012/00843A ZA 201200843 A ZA201200843 A ZA 201200843A ZA 201200843 B ZA201200843 B ZA 201200843B
Authority
ZA
South Africa
Prior art keywords
sogma
chemotherapy
ligands
prevention
treatment
Prior art date
Application number
ZA2012/00843A
Other languages
English (en)
Inventor
Jose Manuel Baeyens-Cabrera
Helmut Heinrich Buschmann
Hernandez Jose Miguel Vela
Daniel Zamanillo-Castanedo
Francisco-Rafael Nieto-Lopez
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of ZA201200843B publication Critical patent/ZA201200843B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2012/00843A 2009-08-14 2012-02-03 Sogma ligands for the prevention or treatment of pain induced by chemotherapy ZA201200843B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09382144A EP2292236A1 (en) 2009-08-14 2009-08-14 Sigma ligands for the prevention or treatment of pain induced by chemotherapy
PCT/EP2010/061720 WO2011018487A1 (en) 2009-08-14 2010-08-12 Sigma ligands for the prevention or treatment of pain induced by chemotherapy

Publications (1)

Publication Number Publication Date
ZA201200843B true ZA201200843B (en) 2012-10-31

Family

ID=41531868

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2012/00843A ZA201200843B (en) 2009-08-14 2012-02-03 Sogma ligands for the prevention or treatment of pain induced by chemotherapy

Country Status (34)

Country Link
US (3) US20120141606A1 (enExample)
EP (2) EP2292236A1 (enExample)
JP (1) JP5922575B2 (enExample)
KR (3) KR101605151B1 (enExample)
CN (1) CN102497864B (enExample)
AR (1) AR077876A1 (enExample)
AU (2) AU2010283761B2 (enExample)
BR (1) BR112012003053A2 (enExample)
CA (1) CA2770441C (enExample)
CO (1) CO6511240A2 (enExample)
CY (1) CY1116697T1 (enExample)
DK (1) DK2464356T3 (enExample)
EC (1) ECSP12011658A (enExample)
ES (1) ES2543645T3 (enExample)
HR (1) HRP20150788T1 (enExample)
HU (1) HUE025642T2 (enExample)
IL (1) IL217911A0 (enExample)
IN (1) IN2012DN02149A (enExample)
MA (1) MA33569B1 (enExample)
MX (1) MX2012001877A (enExample)
MY (1) MY157334A (enExample)
NZ (1) NZ598213A (enExample)
PH (1) PH12012500286A1 (enExample)
PL (1) PL2464356T3 (enExample)
PT (1) PT2464356E (enExample)
RU (1) RU2543382C2 (enExample)
SG (1) SG178338A1 (enExample)
SI (1) SI2464356T1 (enExample)
SM (1) SMT201500189T1 (enExample)
TN (1) TN2012000048A1 (enExample)
TW (1) TWI529168B (enExample)
UA (1) UA108859C2 (enExample)
WO (1) WO2011018487A1 (enExample)
ZA (1) ZA201200843B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
EP2353598A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
EP2388005A1 (en) * 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
EP2426111A1 (en) * 2010-08-09 2012-03-07 Laboratorios Del. Dr. Esteve, S.A. 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms
EP2524694A1 (en) * 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
EP2792352A1 (en) 2013-04-16 2014-10-22 Laboratorios Del. Dr. Esteve, S.A. Alpha-2 adrenoreceptor and sigma receptor ligand combinations
MX2016002892A (es) * 2013-09-12 2016-06-10 Esteve Labor Dr Combinaciones de ligando de receptores sigma y aine.
SG11201604478UA (en) 2013-12-17 2016-07-28 Esteve Labor Dr Gabapentinoids and sigma receptor ligands combinations
SG11201604480PA (en) 2013-12-17 2016-07-28 Esteve Labor Dr SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS
EP3463339B1 (en) 2016-06-06 2023-12-06 Esteve Pharmaceuticals, S.A. Use of sigma receptor ligands in cancer
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
WO2024105225A1 (en) * 2022-11-18 2024-05-23 Universitat De Barcelona Synergistic combinations of a sigma receptor 1 (s1r) antagonist and a soluble epoxide hydrolase inhibitor (sehi) and their use in the treatment of pain

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU11248A1 (ru) 1927-03-29 1929-09-30 В.С. Григорьев Способ очистки антрацена
FR2301250A1 (fr) * 1975-02-21 1976-09-17 Bellon Labor Sa Roger Nouveaux diaryl-1, 4o-aminoalcoxy-3 pyrazoles et leurs sels
RU2417987C2 (ru) * 2004-08-27 2011-05-10 Лабораторьос Дель Др.Эстеве, С.А. Ингибиторы сигма-рецептора
AU2005276590B2 (en) 2004-08-27 2011-05-19 Laboratorios Del Dr. Esteve, S.A. Sigma receptor inhibitors
EP1634872A1 (en) * 2004-08-27 2006-03-15 Laboratorios Del Dr. Esteve, S.A. Pyrazole derivatives as sigma receptor inhibitors
JP2009528315A (ja) * 2006-03-01 2009-08-06 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ シグマ受容体阻害剤としてのピラゾール誘導体
CN101395157A (zh) * 2006-03-01 2009-03-25 伊斯特芬博士实验室有限公司 作为西格玛受体抑制剂的吡唑衍生物

Also Published As

Publication number Publication date
EP2464356A1 (en) 2012-06-20
SMT201500189T1 (it) 2015-09-07
HK1171945A1 (en) 2013-04-12
HUE025642T2 (en) 2016-04-28
DK2464356T3 (en) 2015-07-13
KR20150140419A (ko) 2015-12-15
SG178338A1 (en) 2012-03-29
IN2012DN02149A (enExample) 2015-08-07
IL217911A0 (en) 2012-03-29
CA2770441A1 (en) 2011-02-17
RU2012109554A (ru) 2013-09-20
MY157334A (en) 2016-05-31
SI2464356T1 (sl) 2015-08-31
AU2010283761A1 (en) 2012-03-08
MA33569B1 (fr) 2012-09-01
WO2011018487A1 (en) 2011-02-17
CN102497864B (zh) 2015-07-22
US20160199380A1 (en) 2016-07-14
KR20120055692A (ko) 2012-05-31
BR112012003053A2 (pt) 2016-08-02
CO6511240A2 (es) 2012-08-31
PH12012500286A1 (en) 2015-06-26
CN102497864A (zh) 2012-06-13
NZ598213A (en) 2014-05-30
UA108859C2 (uk) 2015-06-25
HRP20150788T1 (hr) 2015-08-28
EP2292236A1 (en) 2011-03-09
JP5922575B2 (ja) 2016-05-24
AU2016228207B2 (en) 2017-09-07
AU2016228207A1 (en) 2016-11-03
TN2012000048A1 (en) 2013-09-19
ECSP12011658A (es) 2012-03-30
KR101605151B1 (ko) 2016-03-21
AR077876A1 (es) 2011-09-28
US20120141606A1 (en) 2012-06-07
CA2770441C (en) 2017-12-12
AU2010283761B2 (en) 2016-10-13
EP2464356B1 (en) 2015-05-06
CY1116697T1 (el) 2017-03-15
US20160220575A1 (en) 2016-08-04
TW201121959A (en) 2011-07-01
JP2013501754A (ja) 2013-01-17
RU2543382C2 (ru) 2015-02-27
KR20170125951A (ko) 2017-11-15
MX2012001877A (es) 2012-04-11
ES2543645T3 (es) 2015-08-20
PT2464356E (pt) 2015-08-31
PL2464356T3 (pl) 2015-10-30
TWI529168B (zh) 2016-04-11

Similar Documents

Publication Publication Date Title
ZA201200843B (en) Sogma ligands for the prevention or treatment of pain induced by chemotherapy
PT2740793T (pt) Composição de fármacos para o tratamento e/ou a prevenção de cancro
AP3544A (en) Compounds for the treatment of addiction
LT2303021T (lt) Junginiai, skirti vėžio gydymui
PL2740795T3 (pl) Kompozycja lekowa do leczenia nowotworu i/lub zapobiegania nowotworowi
PL2740798T3 (pl) Kompozycja leku do leczenia i/lub zapobiegania nowotworom
HUE047994T2 (hu) Bardoxolon-metil elhízás kezelésére
EP2588419A4 (en) WASTE PROCESSING
IL253293A0 (en) Desferrioxamine complexes of metals for the treatment of diseases related to the immune system
SG2014014724A (en) METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS
ZA201208646B (en) Pharmaceutical combination for the treatment of pain
IL213761A0 (en) Novel ortho-aminoamides for the treatment of cancer
ZA201300079B (en) Conjugates for the prevention or treatment of nicotine addiction
ZA201206204B (en) Treatment or prevention of infection
IL225755B (en) amido derivatives - 6 of epoxymorphinans - a5, 4 for the treatment of pain
PL2731584T3 (pl) Zastosowanie związków oligosacharydowych do zapobiegania i leczenia patologicznych blizn
IL216491A0 (en) Combination therapy for the treatment of multiple myeloma
IL231987A0 (en) Medical combination for cancer treatment
AP2011005893A0 (en) Thia-triaza-cyclopentazulenes as P13-kinases inhibitors for the treatment of cancer.
GB0906210D0 (en) Compounds for the treatment of flaviviral
GB0906202D0 (en) Compounds for the treatment of neoplasia
GB0908699D0 (en) Compounds for the treatment of neoplasia
GB0914476D0 (en) Compounds for the treatment of neoplasia
GB0920317D0 (en) Compounds for the treatment of neoplasia
GB201019110D0 (en) Compounds for the treatment of neoplasia